Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome : a case-control study. / Frøssing, Signe; Nylander, Malin; Aziz, Mubeena; Skouby, Sven O; Kistorp, Caroline; Faber, Jens.
In: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, Vol. 33, No. 1, 01.2017, p. 30-33.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome
T2 - a case-control study
AU - Frøssing, Signe
AU - Nylander, Malin
AU - Aziz, Mubeena
AU - Skouby, Sven O
AU - Kistorp, Caroline
AU - Faber, Jens
PY - 2017/1
Y1 - 2017/1
N2 - BACKGROUND: Polycystic ovary syndrome (PCOS) defined by the Rotterdam criteria does not take into account the unhealthy metabolic profile of the syndrome with increased insulin resistance (IR) and overweight favoring development of type 2 diabetes, hypertension and cardiovascular disease (CVD). We assess three vasoactive peptides associated with CVD in women with PCOS.METHOD: Plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP), copeptin and mid-regional pro-adrenomedullin (MR-proADM) were measured in 98 PCOS patients and 46 age- and BMI-matched healthy women.RESULTS: We found no difference in levels of MR-proANP, copeptin and MR-proADM between the PCOS and control group. Multiple regression analyses on a combined group of PCOS and control subjects demonstrated an inverse correlation between MR-proANP and IR (measured by fasting C-peptide) and a positive correlations between copeptin and IR as well as MR-proADM and BMI. We found no association between peptide levels and different Rotterdam phenotypes.CONCLUSION: Plasma concentrations of MR-proANP, copeptin and MR-proADM were not increased in PCOS compared to age- and BMI-matched controls. Thus, these peptides cannot be used to detect increased risk of CVD in a young PCOS cohort.
AB - BACKGROUND: Polycystic ovary syndrome (PCOS) defined by the Rotterdam criteria does not take into account the unhealthy metabolic profile of the syndrome with increased insulin resistance (IR) and overweight favoring development of type 2 diabetes, hypertension and cardiovascular disease (CVD). We assess three vasoactive peptides associated with CVD in women with PCOS.METHOD: Plasma levels of mid-regional pro-atrial natriuretic peptide (MR-proANP), copeptin and mid-regional pro-adrenomedullin (MR-proADM) were measured in 98 PCOS patients and 46 age- and BMI-matched healthy women.RESULTS: We found no difference in levels of MR-proANP, copeptin and MR-proADM between the PCOS and control group. Multiple regression analyses on a combined group of PCOS and control subjects demonstrated an inverse correlation between MR-proANP and IR (measured by fasting C-peptide) and a positive correlations between copeptin and IR as well as MR-proADM and BMI. We found no association between peptide levels and different Rotterdam phenotypes.CONCLUSION: Plasma concentrations of MR-proANP, copeptin and MR-proADM were not increased in PCOS compared to age- and BMI-matched controls. Thus, these peptides cannot be used to detect increased risk of CVD in a young PCOS cohort.
KW - Journal Article
U2 - 10.1080/09513590.2016.1202915
DO - 10.1080/09513590.2016.1202915
M3 - Journal article
C2 - 27424881
VL - 33
SP - 30
EP - 33
JO - Gynecological Endocrinology
JF - Gynecological Endocrinology
SN - 0951-3590
IS - 1
ER -
ID: 176828685